CY1118492T1 - Φαρμακοτεχνικες μορφες εμβολιου norovirus - Google Patents
Φαρμακοτεχνικες μορφες εμβολιου norovirusInfo
- Publication number
- CY1118492T1 CY1118492T1 CY20171100109T CY171100109T CY1118492T1 CY 1118492 T1 CY1118492 T1 CY 1118492T1 CY 20171100109 T CY20171100109 T CY 20171100109T CY 171100109 T CY171100109 T CY 171100109T CY 1118492 T1 CY1118492 T1 CY 1118492T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical forms
- vlps
- vaccine pharmaceutical
- norovirus vaccine
- norovirus
- Prior art date
Links
- 241001263478 Norovirus Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091008053 gene clusters Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε αντιγονικές και εμβολίου συνθέσεις που περιλαμβάνουν αντιγόνα Norovirus και ανοσοενισχυτικά, ειδικότερα, μείγματα μονοδύναμων VLPs και μείγματα πολυδύναμων VLPs και σε μία μέθοδο για την παρασκευή τόσο μονοδύναμων όσο και πολυδύναμων VLPs, με τα VLPs να περιέχουν πρωτεΐνες καψιδίου από μια ή περισσότερες γενο-ομάδες Norovirus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84791206P | 2006-09-29 | 2006-09-29 | |
US97339207P | 2007-09-18 | 2007-09-18 | |
EP07853688.5A EP2066354B1 (en) | 2006-09-29 | 2007-09-28 | Norovirus vaccine formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118492T1 true CY1118492T1 (el) | 2017-07-12 |
Family
ID=39268804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100109T CY1118492T1 (el) | 2006-09-29 | 2017-01-25 | Φαρμακοτεχνικες μορφες εμβολιου norovirus |
Country Status (17)
Country | Link |
---|---|
US (8) | US7955603B2 (el) |
EP (4) | EP2601970B1 (el) |
JP (3) | JP5476544B2 (el) |
KR (1) | KR101515489B1 (el) |
AU (1) | AU2007303608B2 (el) |
CA (1) | CA2664157C (el) |
CY (1) | CY1118492T1 (el) |
DK (3) | DK2066354T3 (el) |
ES (3) | ES2420136T3 (el) |
HK (1) | HK1184057A1 (el) |
HU (2) | HUE032422T2 (el) |
LT (1) | LT2601970T (el) |
PL (2) | PL2601970T3 (el) |
PT (1) | PT2601970T (el) |
SG (3) | SG174845A1 (el) |
SI (1) | SI2601970T1 (el) |
WO (1) | WO2008042789A1 (el) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2601970B1 (en) * | 2006-09-29 | 2016-10-26 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
PL2134360T3 (pl) | 2007-03-14 | 2016-05-31 | Takeda Vaccines Inc | Oczyszczanie cząstek wirusopodobnych |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
EP2190471A4 (en) * | 2007-09-18 | 2012-05-09 | Ligocyte Pharmaceuticals Inc | METHOD FOR TRANSFERRING A PROTECTIVE REACTION ON NOROVIRES |
AU2009279456B2 (en) * | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
WO2010111586A2 (en) * | 2009-03-27 | 2010-09-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Mucosal immunization |
US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
WO2011079260A2 (en) * | 2009-12-23 | 2011-06-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Stabilized virus like particles having enhanced mucosal immunogenicity |
CN102791286B (zh) * | 2010-01-21 | 2017-08-08 | 莱戈赛特医药股份有限公司 | 杯状病毒病毒样颗粒上靶定异源抗原的呈递 |
EP2689785B1 (en) * | 2010-04-15 | 2021-05-19 | Shin Nippon Biomedical Laboratories, Ltd. | Method for generating dry vaccine powder formulation for inranasal delivery |
AU2012244077B2 (en) * | 2010-04-15 | 2015-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Methods and compositions for intranasal delivery |
EP2731621B1 (en) | 2011-07-11 | 2017-11-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
US20140017257A1 (en) * | 2012-07-11 | 2014-01-16 | Xi Jiang | IgY From Norovirus P Particles And Their Derivatives |
EP3745128A1 (en) * | 2012-12-28 | 2020-12-02 | Cellestis Limited | A cell mediated immune response assay |
WO2014145245A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
US9975923B2 (en) | 2013-03-15 | 2018-05-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
JP2015015931A (ja) | 2013-07-12 | 2015-01-29 | 株式会社Umnファーマ | ウイルス様粒子を含む培養物の製造方法 |
JP2015017065A (ja) * | 2013-07-12 | 2015-01-29 | 株式会社Umnファーマ | ノロウイルスのウイルス様粒子を含む医薬組成物 |
JP6479305B2 (ja) | 2013-07-12 | 2019-03-06 | 株式会社Umnファーマ | ウイルス様粒子の精製方法 |
EP3021871A1 (en) | 2013-07-17 | 2016-05-25 | Dow Global Technologies LLC | Composition for application to a mucosa comprising a methylcellulose |
CN106103720A (zh) | 2013-10-03 | 2016-11-09 | 武田疫苗股份有限公司 | 自细胞系检测和除去弹状病毒的方法 |
WO2015093452A1 (ja) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
CA3000329A1 (en) * | 2015-08-28 | 2017-03-09 | Ology Bioservices, Inc. | Norovirus vaccine |
KR101915740B1 (ko) * | 2016-03-18 | 2018-11-06 | (주)인테라 | 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질 |
CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
WO2018182983A1 (en) | 2017-03-28 | 2018-10-04 | Children's Hospital Medical Center | Norovirus s particle based vaccines and methods of making and using same |
JP2021503962A (ja) | 2017-11-30 | 2021-02-15 | メディカゴ インコーポレイテッド | 改変ノロウイルスvp1タンパク質及び改変ノロウイルスvp1タンパク質を含むvlp |
US11633467B2 (en) | 2018-02-15 | 2023-04-25 | Icon Genetics Gmbh | Immunogenic composition and vaccine for generating an immune response to norovirus |
JP6713013B2 (ja) * | 2018-03-06 | 2020-06-24 | 株式会社イーダブルニュートリション・ジャパン | 貝類のノロウイルス不活化方法 |
WO2020010428A1 (en) | 2018-07-13 | 2020-01-16 | Medicago Inc. | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
WO2020041192A1 (en) | 2018-08-20 | 2020-02-27 | Takeda Vaccines, Inc. | Vlp formulations |
WO2020061067A2 (en) * | 2018-09-17 | 2020-03-26 | Board Of Regents, The University Of Texas System Texas System | Compositions and methods for treating bone injury |
US11523988B2 (en) | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
EP3698773A1 (en) | 2019-02-21 | 2020-08-26 | Università degli Studi di Parma | Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination |
JP2022522891A (ja) | 2019-03-12 | 2022-04-20 | アイコン ジェネティクス ゲーエムベーハー | 安定性が改善されたノロウイルス様粒子 |
CN115023219A (zh) * | 2019-08-13 | 2022-09-06 | 艾尔特免疫公司 | 治疗剂的有效性及其施用途径 |
EP4340874A1 (en) | 2021-05-21 | 2024-03-27 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
CN117330750A (zh) * | 2023-12-01 | 2024-01-02 | 北京生物制品研究所有限责任公司 | 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
AU1893592A (en) * | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
CA2133339A1 (en) | 1992-04-08 | 1993-10-09 | Jennifer S. Rota | Wild-type measles virus glycoproteins: vaccine and detection method therefor |
AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
JP3863559B2 (ja) | 1994-05-16 | 2006-12-27 | メルク エンド カンパニー インコーポレーテッド | 乳頭腫ウィルスワクチン |
US5645051A (en) * | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5861241A (en) * | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US5834015A (en) | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
DE69822452T2 (de) | 1997-04-08 | 2006-04-20 | Merck & Co., Inc. | Stabilisierte humane papillomaviruszusammensetzungen |
WO1998050071A1 (en) | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
CA2339034C (en) | 1998-08-14 | 2010-10-12 | Merck & Co., Inc. | Process for purifying human papillomavirus virus-like particles |
WO2000035479A1 (en) | 1998-12-17 | 2000-06-22 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
SI1150712T1 (sl) | 1999-02-05 | 2009-02-28 | Merck & Co Inc | Pripravek cepiva proti humanem papiloma virusu |
WO2000079280A1 (fr) | 1999-06-22 | 2000-12-28 | Japan As Represented By Director-General National Institute Of Infectious Diseases | Materiel de detection de srsv |
AU2003213060A1 (en) | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
CA2849556A1 (en) | 2002-04-11 | 2003-10-23 | Vu Truong-Le | Preservation of bioactive materials by freeze dried foam |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
US20040033585A1 (en) | 2002-06-07 | 2004-02-19 | Mccormick Alison A. | Flexible vaccine assembly and vaccine delivery platform |
AU2003242742B2 (en) | 2002-06-20 | 2009-04-30 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
JP4675317B2 (ja) | 2003-01-30 | 2011-04-20 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | アジュバント化インフルエンザワクチン |
EP1599188A2 (en) | 2003-02-20 | 2005-11-30 | Becton, Dickinson and Company | POWDER FORMULATIONS OF RECOMBINANT STAPHYLOCOCCAL, ENTEROTOXIN B (<SB>R</SB>SEB) MADE BY ATMOSPHERIC SPRAY-FREEZE DRYING FOR IMPROVED VACCINATION |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
WO2005030806A2 (en) | 2003-09-24 | 2005-04-07 | Montana State University | Norovirus monoclonal antibodies and peptides |
WO2005037223A2 (en) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
US7481997B1 (en) * | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
US8029802B2 (en) | 2004-10-20 | 2011-10-04 | Sanofi Pasteur Biologics Co. | Vaccines against Japanese encephalitis virus and West Nile virus |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
WO2006074303A2 (en) | 2005-01-05 | 2006-07-13 | Philadelphia Health And Education Corporation | Delivery vehicles, bioactive substances and viral vaccines |
EP1846439A2 (en) | 2005-01-31 | 2007-10-24 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
ES2385045T3 (es) | 2005-02-18 | 2012-07-17 | Novartis Vaccines And Diagnostics, Inc. | Inmunógenos de Escherichia coli uropatogénica |
PL1868642T3 (pl) | 2005-03-18 | 2013-10-31 | Cytos Biotechnology Ag | Białka fuzyjne alergenów kocich i ich zastosowania |
EP1885394A4 (en) | 2005-06-01 | 2009-10-21 | Dow Global Technologies Inc | PRODUCTION OF MULTIVALENT PARTICLES LIKE VIRUSES |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
ES2514316T3 (es) | 2005-11-22 | 2014-10-28 | Novartis Vaccines And Diagnostics, Inc. | Partículas similares a virus (VLPs) de Norovirus y Sapovirus |
JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスgiの高感度検出方法 |
EP2601970B1 (en) | 2006-09-29 | 2016-10-26 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
CA2671629C (en) | 2006-12-06 | 2017-08-15 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
US8474614B2 (en) * | 2007-03-14 | 2013-07-02 | BBY Solutions | Protective container for a flat screen monitor |
PL2134360T3 (pl) | 2007-03-14 | 2016-05-31 | Takeda Vaccines Inc | Oczyszczanie cząstek wirusopodobnych |
EP2190471A4 (en) | 2007-09-18 | 2012-05-09 | Ligocyte Pharmaceuticals Inc | METHOD FOR TRANSFERRING A PROTECTIVE REACTION ON NOROVIRES |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
AU2009279456B2 (en) | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
JP2012515752A (ja) | 2009-01-22 | 2012-07-12 | ファーマシーネ,インコーポレイテッド | 安定なワクチン組成物とその使用方法 |
ES2552383T3 (es) | 2009-02-10 | 2015-11-27 | Novartis Ag | Regímenes de vacuna de la gripe para cepas asociadas a pandemias |
US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
CN102791286B (zh) | 2010-01-21 | 2017-08-08 | 莱戈赛特医药股份有限公司 | 杯状病毒病毒样颗粒上靶定异源抗原的呈递 |
CN107029222A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
EP2731621B1 (en) | 2011-07-11 | 2017-11-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
-
2007
- 2007-09-28 EP EP13157573.0A patent/EP2601970B1/en not_active Revoked
- 2007-09-28 PL PL13157573T patent/PL2601970T3/pl unknown
- 2007-09-28 ES ES07853688T patent/ES2420136T3/es active Active
- 2007-09-28 SG SG2011071123A patent/SG174845A1/en unknown
- 2007-09-28 DK DK07853688.5T patent/DK2066354T3/da active
- 2007-09-28 KR KR1020097008725A patent/KR101515489B1/ko active IP Right Grant
- 2007-09-28 EP EP13173005.3A patent/EP2641613A1/en not_active Withdrawn
- 2007-09-28 DK DK13157572.2T patent/DK2601969T3/en active
- 2007-09-28 DK DK13157573.0T patent/DK2601970T3/en active
- 2007-09-28 PT PT131575730T patent/PT2601970T/pt unknown
- 2007-09-28 CA CA2664157A patent/CA2664157C/en active Active
- 2007-09-28 JP JP2009530639A patent/JP5476544B2/ja active Active
- 2007-09-28 EP EP07853688.5A patent/EP2066354B1/en active Active
- 2007-09-28 PL PL13157572.2T patent/PL2601969T3/pl unknown
- 2007-09-28 US US12/093,921 patent/US7955603B2/en active Active
- 2007-09-28 ES ES13157573.0T patent/ES2618885T3/es active Active
- 2007-09-28 HU HUE13157573A patent/HUE032422T2/en unknown
- 2007-09-28 EP EP13157572.2A patent/EP2601969B1/en active Active
- 2007-09-28 ES ES13157572.2T patent/ES2577833T3/es active Active
- 2007-09-28 AU AU2007303608A patent/AU2007303608B2/en active Active
- 2007-09-28 SI SI200731885A patent/SI2601970T1/sl unknown
- 2007-09-28 HU HUE13157572A patent/HUE028978T2/en unknown
- 2007-09-28 SG SG10201502490YA patent/SG10201502490YA/en unknown
- 2007-09-28 LT LTEP13157573.0T patent/LT2601970T/lt unknown
- 2007-09-28 SG SG10202012986SA patent/SG10202012986SA/en unknown
- 2007-09-28 WO PCT/US2007/079929 patent/WO2008042789A1/en active Application Filing
-
2010
- 2010-06-16 US US12/816,495 patent/US8431116B2/en active Active
-
2011
- 2011-12-20 US US13/330,854 patent/US20120093861A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/837,885 patent/US9272028B2/en active Active
- 2013-03-15 US US13/836,446 patent/US10010599B2/en active Active
- 2013-03-15 US US13/837,653 patent/US9308249B2/en active Active
- 2013-06-24 JP JP2013131559A patent/JP5898133B2/ja active Active
- 2013-10-14 HK HK13111536.3A patent/HK1184057A1/zh unknown
-
2015
- 2015-07-10 US US14/796,714 patent/US9861691B2/en active Active
- 2015-10-05 JP JP2015197633A patent/JP6134364B2/ja active Active
-
2017
- 2017-01-25 CY CY20171100109T patent/CY1118492T1/el unknown
-
2018
- 2018-05-31 US US15/994,887 patent/US10512682B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
CY1121672T1 (el) | Αντισωματα που προσδενουν τα il-17a και il-17f | |
CY1120319T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1120328T1 (el) | Συνθεση εμβολιου περιεχουσα συνθετικο ανοσοενισχυτικο | |
CY1117331T1 (el) | Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων | |
CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
CY1123952T1 (el) | Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
CY1120622T1 (el) | Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
CY1119849T1 (el) | Προ-συντηξης rsv f αντιγονα | |
CY1115932T1 (el) | Σκευασμα αντισωματος | |
CY1115999T1 (el) | Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη | |
CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
CY1115935T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CU20120095A7 (es) | Antagonistas de pcsk9 | |
CY1115639T1 (el) | Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου | |
MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
CY1115147T1 (el) | Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17 | |
ECSP066683A (es) | Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes | |
CY1113546T1 (el) | Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων |